Payment overview · 2025
General Payments
$272.46
15 reported records · 7 companies
Healthcare provider profile · identity verified
Douglas B Carr, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LOGAN, OH · NPI 1912909219
Verified facts
What the public records show
CMS Open Payments records show Douglas B Carr, M.D. received $272.46 in general payments during 2025 across 15 reported records.
Lilly USA, LLC accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.96 | 27.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $64.62 | 23.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.10 | 15.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.79 | 12.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.51 | 10.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.03 | 5.2% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $13.45 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $227.46 | 14 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $64.62 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.10 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.96 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.96 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.51 | 2 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $13.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 66 |
| Omeprazole | Omeprazole | 166 | 44 |
| Metformin Hcl | Metformin Hcl | 162 | 39 |
| Lisinopril | Lisinopril | 146 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 18 |
| Losartan Potassium | Losartan Potassium | 116 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 32 |
| Alprazolam | Alprazolam | 112 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 35 |
| Gabapentin | Gabapentin | 109 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 108 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 27 |
| Jardiance | Empagliflozin | 104 | 32 |
| Januvia | Sitagliptin Phosphate | 94 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 29 |
| Sertraline Hcl | Sertraline Hcl | 90 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 26 |
| Meloxicam | Meloxicam | 82 | 25 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 79 | 53 |
| Metformin Hcl Er | Metformin Hcl | 77 | 23 |
| Furosemide | Furosemide | 75 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 21 |
| Ozempic | Semaglutide | 68 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 17 |
| Carvedilol | Carvedilol | 60 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 16 |
| Simvastatin | Simvastatin | 60 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 56 | 56 |
| Potassium Chloride | Potassium Chloride | 50 | 15 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Azithromycin | Azithromycin | 47 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Celecoxib | Celecoxib | 42 | 12 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Prednisone | Prednisone | 36 | 24 |
| Xarelto | Rivaroxaban | 36 | 12 |
| Eliquis | Apixaban | 35 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $272.46 · 15 records | Lilly USA, LLC | CAPVAXIVE, CeQur Simplicity, Cologuard Collection Kit, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, MOUNJARO, Ozempic, QULIPTA, UBRELVY, VAXELIS, VAXNEUVANCE, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error